Early EV dose reduction in advanced urothelial cancer ↘️ treatment interruption risk by half, yet survival stayed the same.
@JAMAOnc@OncoAlert@WorldBladderCan@Uromigos
https://t.co/sbC1ZA95EW
In a new study published in @CCR_AACR, @DanaFarber researchers found the effects of immunotherapy can last after treatment stops in patients with advanced non-small cell lung cancer. @DFarberThoracic
Read more: https://t.co/GIjAvnNQT7
50 years of vaccines = 154 million lives saved!
Since 1974, childhood vaccines have been the biggest driver of infant survival, preventing 40% of infant deaths globally. Immunization isn’t just protection—it’s a lifesaver. #VaccinesWork#PublicHealth@TheLancet@WHO@CDCgov@EricTopol@Atul_Gawande
https://t.co/mDjIFYrWVK
💊 7 vs. 14 Days of Antibiotics?
For bloodstream infections, 7 days = 14 days in 90-day mortality! @NEJM
Mortalities:
7 days: 14.5%
14 days: 16.1%
Less is more!!! @oergonul1
https://t.co/ifHmfdOmvL
This morning I have found this on my desk... I am so proud of this achievement! 😁 Thanks 🙏 to all investigators & @EUplatinum for supporting Academic Research in GU cancers.
Stay tuned 🛜 for other news from TIDE-A trial! @Uroweb@urofocus@OncoAlert@oncodaily@GUOncologyNow@OncLive
Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney - Clinical Genitourinary Cancer https://t.co/T27JoR8fib
The potential of RBC-based scores to improve prognostic systems in metastatic renal cell carcinoma. Identifying patients with better prognosis and exploring molecular correlates could refine treatment strategies, #mRCC#CancerResearch#Oncology#IUCS@OncoAlert@OncoViews
ITALIAN REGISTRY ON RARE UROLOGICAL TUMORS (MEET-URO-23): THE FIRST ANALYSIS ON COLLECTING DUCT CARCINOMA OF THE KIDNEY - Clinical Genitourinary Cancer https://t.co/T27JoR7HsD